New partnership chair, Amy Chonis, gave her address at the 2021 GHP Annual Meeting. Sky Noir Photography by Bill Dickinson/Getty Images

With 2020 in the rearview, the Greater Houston Partnership is looking into the new year with a new board chair. In the GHP's 2021 Annual Meeting, the organization introduced how important developing the innovation community is in Houston.

In her remarks, this year's Partnership Chair Amy Chronis, who is the Houston managing partner at Deloitte, shared what she hopes to inspire in her tenure. Her statement can be boiled down to three major points.

It's time to modernize Houston's economy

Chronis says it's time to focus on tech and innovation — and that requires support from all aspects of the city.

"Here in Houston, we must be laser-focused on building a strong, diverse, 21st century economy," she says. "Over the past few years, entrepreneurs, investors, academic institutions, local government, and the corporate sector have come together to unite, grow, and promote Houston's startup ecosystem. The progress since 2016 is staggering."

Since 2016, Chronis says, venture capital investment in Houston has increased almost 250 percent to a record $714 million dollars raised in 2020. Additionally, she calls out 30 new startup development organizations that have sprung up around town — like the East End Maker Hub, The Cannon, The Ion, Greentown Labs, and so much more.

Chronis also calls out the importance of educational institutions, such as Rice University and the University of Houston.

It's the industries that drive innovation

There is a growing need to diversify Houston's economy away from just oil and gas, Chronis says it's Houston's core industries — energy, life sciences, aerospace, along with manufacturing and global logistics — that have made transformative steps.

"We've got momentum, but we still need to double down with work to do," Chronis says, identifying energy, life sciences, and aerospace as three pillars to drive success.

Regarding energy, Chronis touts Greentown Labs opening in Houston — but warns it's increasingly important to have big corporations promote the energy transition.

"From the super majors to the service firms and the increasing presence of renewable companies, Houston is at the forefront of driving the Energy 2.0 sector," she says.

When it comes to health care, Chronis remarks on the Texas Medical Center's success with the TMC Innovation Institute and the development of TMC3, a 37-acre research commercialization campus.

"What's special about TMC3 is that it will create collaboration and innovation at scale," she adds. "It will be a catalyst that will advance Houston's position as the Third Coast for Life Sciences."

Lastly, Houston must maintain its moniker as the Space City — and the city has a lot of opportunities to do that with the development of the Houston Spaceport at Ellington Airport and the NASA Johnson Space Center.

"Houston is already home to a rich talent pool of nearly 23,000 aerospace manufacturing professionals and more than 500 aerospace and aviation companies and institutions, but the potential is so much greater," Chronis says.

Houston needs to focus on four areas to "drive a technological renaissance"

Chronis concludes her speech with some calls to action. She first acknowledges that corporations ask themselves about how they are promoting and valuing innovation.

"We must be committed to inspiring, cultivating and rewarding technological innovation," Chronis says. "How is your company partnering with startups, higher education institutions and other stakeholders to drive innovation?"

Next, Chronis calls out Houston's global diversity as a differentiator when it comes to attracting companies to Houston, and she cites HPE as an example.

"We know there are hundreds of tech companies in the Valley, and up and down the West and East coasts that are striving to build global diversity within their companies," she says. "There is no better place than Houston to do this."

Third, Chronis calls for everyone — from corporates to educations — to empower the next generation of innovators.

And, finally, she says it's time to spread the word about Houston.

"We are modern, sophisticated, and at our core, an incredibly global city. Global in a way that sets us apart from most U.S. metros," she says. "So, as we embark on this work to drive Houston's technology renaissance, we must ensure perceptions of Houston are aligned with reality."

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Houston hospital names leading cancer scientist as new academic head

new hire

Houston Methodist Academic Institute has named cancer clinician and scientist Dr. Jenny Chang as its new executive vice president, president, CEO, and chief academic officer.

Chang was selected following a national search and will succeed Dr. H. Dirk Sostman, who will retire in February after 20 years of leadership. Chang is the director of the Houston Methodist Dr. Mary and Ron Neal Cancer Center and the Emily Herrmann Presidential Distinguished Chair in Cancer Research. She has been with Houston Methodist for 15 years.

Over the last five years, Chang has served as the institute’s chief clinical science officer and is credited with strengthening cancer clinical trials. Her work has focused on therapy-resistant cancer stem cells and their treatment, particularly relating to breast cancer.

Her work has generated more than $35 million in funding for Houston Methodist from organizations like the National Institutes of Health and the National Cancer Institute, according to the health care system. In 2021, Dr. Mary Neal and her husband Ron Neal, whom the cancer center is now named after, donated $25 million to support her and her team’s research on advanced cancer therapy.

In her new role, Chang will work to expand clinical and translational research and education across Houston Methodist in digital health, robotics and bioengineered therapeutics.

“Dr. Chang’s dedication to Houston Methodist is unparalleled,” Dr. Marc L. Boom, Houston Methodist president and CEO, said in a news release. “She is committed to our mission and to helping our patients, and her clinical expertise, research innovation and health care leadership make her the ideal choice for leading our academic mission into an exciting new chapter.”

Chang is a member of the American Association of Cancer Research (AACR) Stand Up to Cancer Scientific Advisory Council. She earned her medical degree from Cambridge University in England and completed fellowship training in medical oncology at the Royal Marsden Hospital/Institute for Cancer Research. She earned her research doctorate from the University of London.

She is also a professor at Weill Cornell Medical School, which is affiliated with the Houston Methodist Academic Institute.

Texas A&M awarded $1.3M federal grant to develop clean energy tech from electronic waste

seeing green

Texas A&M University in College Station has received a nearly $1.3 million federal grant for development of clean energy technology.

The university will use the $1,280,553 grant from the U.S. Department of Energy to develop a cost-effective, sustainable method for extracting rare earth elements from electronic waste.

Rare earth elements (REEs) are a set of 17 metallic elements.

“REEs are essential components of more than 200 products, especially high-tech consumer products, such as cellular telephones, computer hard drives, electric and hybrid vehicles, and flat-screen monitors and televisions,” according to the Eos news website.

REEs also are found in defense equipment and technology such as electronic displays, guidance systems, lasers, and radar and sonar systems, says Eos.

The grant awarded to Texas A&M was among $17 million in DOE grants given to 14 projects that seek to accelerate innovation in the critical materials sector. The federal Energy Act of 2020 defines a critical material — such as aluminum, cobalt, copper, lithium, magnesium, nickel, and platinum — as a substance that faces a high risk of supply chain disruption and “serves an essential function” in the energy sector.

“DOE is helping reduce the nation’s dependence on foreign supply chains through innovative solutions that will tap domestic sources of the critical materials needed for next-generation technologies,” says U.S. Energy Secretary Jennifer Granholm. “These investments — part of our industrial strategy — will keep America’s growing manufacturing industry competitive while delivering economic benefits to communities nationwide.”

------

This article originally appeared on EnergyCapital.

Biosciences startup becomes Texas' first decacorn after latest funding

A Dallas-based biosciences startup whose backers include millionaire investors from Austin and Dallas has reached decacorn status — a valuation of at least $10 billion — after hauling in a series C funding round of $200 million, the company announced this month. Colossal Biosciences is reportedly the first Texas startup to rise to the decacorn level.

Colossal, which specializes in genetic engineering technology designed to bring back or protect various species, received the $200 million from TWG Global, an investment conglomerate led by billionaire investors Mark Walter and Thomas Tull. Walter is part owner of Major League Baseball’s Los Angeles Dodgers, and Tull is part owner of the NFL’s Pittsburgh Steelers.

Among the projects Colossal is tackling is the resurrection of three extinct animals — the dodo bird, Tasmanian tiger and woolly mammoth — through the use of DNA and genomics.

The latest round of funding values Colossal at $10.2 billion. Since launching in 2021, the startup has raised $435 million in venture capital.

In addition to Walter and Tull, Colossal’s investors include prominent video game developer Richard Garriott of Austin and private equity veteran Victor Vescov of Dallas. The two millionaires are known for their exploits as undersea explorers and tourist astronauts.

Aside from Colossal’s ties to Dallas and Austin, the startup has a Houston connection.

The company teamed up with Baylor College of Medicine researcher Paul Ling to develop a vaccine for elephant endotheliotropic herpesvirus (EEHV), the deadliest disease among young elephants. In partnership with the Houston Zoo, Ling’s lab at the Baylor College of Medicine has set up a research program that focuses on diagnosing and treating EEHV, and on coming up with a vaccine to protect elephants against the disease. Ling and the BCMe are members of the North American EEHV Advisory Group.

Colossal operates research labs Dallas, Boston and Melbourne, Australia.

“Colossal is the leading company working at the intersection of AI, computational biology, and genetic engineering for both de-extinction and species preservation,” Walter, CEO of TWG Globa, said in a news release. “Colossal has assembled a world-class team that has already driven, in a short period of time, significant technology innovations and impact in advancing conservation, which is a core value of TWG Global.”

Well-known genetics researcher George Church, co-founder of Colossal, calls the startup “a revolutionary genetics company making science fiction into science fact.”

“We are creating the technology to build de-extinction science and scale conservation biology,” he added, “particularly for endangered and at-risk species.”